Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / COX7A1



This biomarker is also known as:
  • COX7A,
  • cytochrome c oxidase subunit VIIa polypeptide 1 (muscle),
  • cytochrome c oxidase subunit VIIa-muscle,
  • cytochrome c oxidase subunit VIIa heart/muscle isoform,
  • Cytochrome c oxidase subunit VIIa-muscle,
  • cytochrome c oxidase subunit VIIa-H,
  • cytochrome c oxidase subunit 7A1, mitochondrial,
  • COX7AM,
  • Cytochrome c oxidase subunit VIIa-M,
  • cytochrome c oxidase subunit VIIa-heart,
  • COX7AH,
  • cytochrome c oxidase subunit VIIa-M,
  • Cytochrome c oxidase subunit VIIa-heart,
  • Cytochrome c oxidase subunit VIIa-H,

View in BioMuta


COX7A1, cytochrome c oxidase subunit VIIa polypeptide 1 (muscle), is one of the polypeptide chains of cytochrome c oxidase, the terminal component of the mitochondrial respiratory chain. This polypeptide is present only in muscle tissues. Other polypeptides of subunit VIIa are present in both muscle and nonmuscle tissues, and are encoded by different genes.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

COX7A1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.